Broad Institute, MD Anderson Cancer Center designated as Genome Characterization Centers

BROAD INSTITUTE and MD ANDERSON CANCER CENTER were designated the Genome Characterization Centers in a five-year project supported by the NCI to characterize the genomic changes found in tumors.

GCC’s funding comes via a research subcontract with Leidos Biomedical Research Inc., operations and technical support contractor for NCI’s Frederick National Laboratory for Cancer Research.

The centers will provide Whole Genome, Whole Exome and RNA sequencing to support three main project areas:

The Exceptional Responders Initiative aimed at discovering and understanding the molecular events involved in extraordinary individual responses to otherwise unsuccessful targeted experimental cancer therapies.
The ALCHEMIST Project (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) aimed at providing molecular data to support biomarker classification and genomic characterization of lung cancer patients enrolled in clinical trials.
The Cancer Driver Discovery Project aimed at providing additional statistical power to discover driver mutations in lung, colon and ovarian cancer.

The project was funded under Contract No. HHSN261200800001E.

DOWNLOAD THE PDF

Table of Contents

YOU MAY BE INTERESTED IN

Podcast

The Galleri MCD vote: What FDA asked its advisors to ignore

In this episode of The Cancer Letter Podcast, Paul Goldberg, editor and publisher of The Cancer Letter, Jacquelyn Cobb, managing editor, discuss the Sept. 23 meeting of the FDA Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee, during which the panel voted in favor of Galleri, the multi-cancer detection test from GRAIL Inc., to become the first multi-cancer detection test to receive regulatory approval.

September 30, 2026

Podcast The Directors

The Directors: Two Gulf Coast cancer center directors on why NCI designation matters—and why they want it
Lucio Miele and Raghu Kalluri: Science and technology have changed what an aspiring cancer center must accomplish

What should a cancer center look like in an era of AI, genomics, complex patient populations, rising costs, and declining public trust in science?

September 25, 2026

Vol.52 No.35

By Claire Marie Porter and Paul Goldberg

News Analysis Regulatory News

FDA advisory committee votes in favor of Galleri approval, but calls for removal of “early” detection claims
Clinical benefit will not be considered for approval, FDA says

The FDA Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee voted in favor of Galleri to become the first multi-cancer detection test to receive regulatory approval.

September 25, 2026

Vol.52 No.35

By Jacquelyn Cobb and Sara Willa Ernst

News Analysis

Trump weighs—and abandons—an executive order that would give OMB veto power over NIH grants

The White House last week considered, but ultimately abandoned, a plan to create a panel that would review NIH grants in an effort to weed out projects the administration regards as “woke.”

When did stage 3B lung cancer become “early stage”?

My recent column about Merck’s television commercial for perioperative Keytruda left me with a question I could not shake.

September 25, 2026

Vol.52 No.35

By Raja M. Flores

How biology is reshaping breast cancer care

Breast cancer treatment has changed dramatically over the past decade. One of the most important advances has been our growing ability to understand the biology of each patient’s cancer and use those insights to guide treatment decisions more precisely. That shift is helping make personalized cancer care a reality.

September 25, 2026

Vol.52 No.35

By Hope S. Rugo

Broad Institute, MD Anderson Cancer Center designated as Genome Characterization Centers

YOU MAY BE INTERESTED IN

The Galleri MCD vote: What FDA asked its advisors to ignore

The Directors: Two Gulf Coast cancer center directors on why NCI designation matters—and why they want it
Lucio Miele and Raghu Kalluri: Science and technology have changed what an aspiring cancer center must accomplish

FDA advisory committee votes in favor of Galleri approval, but calls for removal of “early” detection claims
Clinical benefit will not be considered for approval, FDA says

Trump weighs—and abandons—an executive order that would give OMB veto power over NIH grants

When did stage 3B lung cancer become “early stage”?

How biology is reshaping breast cancer care

Renew today!

Subscriber content

Never miss an issue!

Login

Broad Institute, MD Anderson Cancer Center designated as Genome Characterization Centers

YOU MAY BE INTERESTED IN

The Galleri MCD vote: What FDA asked its advisors to ignore

The Directors: Two Gulf Coast cancer center directors on why NCI designation matters—and why they want itLucio Miele and Raghu Kalluri: Science and technology have changed what an aspiring cancer center must accomplish

FDA advisory committee votes in favor of Galleri approval, but calls for removal of “early” detection claimsClinical benefit will not be considered for approval, FDA says

Trump weighs—and abandons—an executive order that would give OMB veto power over NIH grants

When did stage 3B lung cancer become “early stage”?

How biology is reshaping breast cancer care

Never miss an issue!

Login

The Directors: Two Gulf Coast cancer center directors on why NCI designation matters—and why they want it
Lucio Miele and Raghu Kalluri: Science and technology have changed what an aspiring cancer center must accomplish

FDA advisory committee votes in favor of Galleri approval, but calls for removal of “early” detection claims
Clinical benefit will not be considered for approval, FDA says